Medical Nutrition USA Introduces Diff-Stat(TM) to Combat Antibiotic-Associated Intestinal Maladies
24 Novembre 2009 - 2:30PM
Marketwired
Medical Nutrition USA, Inc. (NASDAQ: MDNU), a developer and
distributor of uniquely engineered, nutrition-medicine products,
announced the introduction of Diff-Stat(TM), a new supplement
containing pre- and probiotics to help restore and maintain
beneficial bacteria that prevent the onset of antibiotic-associated
diarrhea (AAD) and clostridium difficile (C-diff).
C-diff is a bacterium that causes diarrhea and more serious
intestinal conditions. It is one of the chief causes of
hospital-acquired diarrhea in the U.S., responsible for
approximately three million cases per year of diarrhea and colitis
treated at an annual cost of more than $1.1 billion.(1)
Both C-diff and AAD pose serious risks to the health of elderly
and frail patients from the wasting effects of diarrhea and
intestinal damage. The likelihood that such conditions will arise
in this population is increased when patients take antibiotics,
which can eliminate the beneficial intestinal microbiota that help
prevent the onset of AAD and C-diff.
Diff-Stat(TM), which is available as a powder or as a chewable
tablet, contains a combination of clinically proven ingredients
that help combat the effects of antibiotics on intestinal
microbiota by providing increased beneficial bacteria to the colon,
destroying toxins and toxin binding sites and stimulating the
growth of beneficial bacteria.
Strong results in patients on antibiotic regimens
A recently completed survey of 82 residents taking Diff-Stat(TM)
while undergoing antibiotic therapy at 17 long-term care facilities
showed that 96 percent of the survey population did not develop AAD
and 100 percent did not develop C-diff during, and after
completing, antibiotic therapy. Participants were given one
chewable tablet twice daily within three days of starting
antibiotic therapy and continuing for two weeks after completing
antibiotic therapy.
Other notable outcomes of the survey included an overwhelming
response (99 percent) from clinicians that Diff-Stat(TM) was easy
to administer, and that patient compliance and taste acceptability
were good.
"Diff-Stat(TM) was developed in response to clinicians' concerns
about the prevalent incidence of AAD and C-diff in the long-term
care and acute care facilities that make up Medical Nutrition's
primary market," said Frank A. Newman, Medical Nutrition's Chairman
and Chief Executive Officer. "Diff-Stat is further evidence of our
company's continuing ability to develop effective new products that
address clinicians' needs in easy-to-administer and cost-effective
forms."
"As with our prior industry-first products such as Pro-Stat®,
UTI-Stat(TM) and Pro-Stat® AWC (Advanced Wound Care), Diff-Stat(TM)
expands the therapeutic options available to clinicians while
creating a new revenue stream that we expect will grow
significantly as institutions come to rely upon the products'
effectiveness and ease of administration."
(1) Blossom DB, McDonald C.; The Challenges Posed by Reemerging
Clostridium Difficile Infection. CID. 2007; 45:222-227.
About Medical Nutrition USA, Inc.
Medical Nutrition USA develops and distributes products for the
nutritionally at risk who are under medical supervision. Its
products are used primarily in long-term care facilities,
hospitals, dialysis clinics and bariatric clinics. The Company's
product lines include Pro-Stat®, Fiber-Stat® and UTI-Stat(TM), as
well as private label products. Additional information is available
at www.mdnu.com.
This news release contains forward-looking statements that are
subject to certain risks and uncertainties. Although we believe
that the expectations reflected in any of our forward-looking
statements are reasonable, actual results could differ materially
from those projected or assumed. Risks and uncertainties that could
cause or contribute to such material difference include, but are
not limited to, general economic conditions, changes in customer
demand, changes in trends in the nursing home, renal care, health
food and bariatric surgery markets, changes in competitive pricing
for products, and the impact of our competitors' new product
introductions. Our future financial condition and results of
operations, as well as any forward-looking statements are subject
to change and inherent risk and uncertainties. Other important
factors that may cause actual results to differ materially from
those expressed in forward-looking statements is contained in the
Medical Nutrition USA, Inc. Annual Report on Form 10-K for the year
ended January 31, 2009 as filed with the Securities and Exchange
Commission on April 24, 2009 and Form 10-Q for the quarter ended
July 31, 2009 filed on Sept. 11, 2009.
Contacts: Medical Nutrition USA, Inc. Frank J. Kimmerling Vice
President/CFO 800.221.0308 Email Contact Investor Relations Adam
Friedman 212.981.2529 x18 Email Contact
Medical Nutrition Usa (MM) (NASDAQ:MDNU)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Medical Nutrition Usa (MM) (NASDAQ:MDNU)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024